Ms Davies has over 20 years’ professional experience in virus research and molecular biology, including extensive experience in the development and manufacture of CAVATAK at Viralytics. At ImmVirX, she leads CMC operations, including viral seed and cell bank production, process and analytical assay development, and oversight of GMP drug substance manufacture.

In her most recent years at Viralytics, she served as Manager, Manufacturing Science. In that role, she was responsible for the technical oversight of external manufacturing of both raw materials and drug substances at GMP-contract manufacturing sites located in the USA and the UK.

Following the acquisition of Viralytics by Merck & Co., Inc., Ms Davies played a key role in the technical transfer of the CAVATAK manufacturing and analytical testing programmes. As part of this effort, she joined the project team at the Merck West Point Facility in Pennsylvania, USA for the continued on-site technical support of the drug substance manufacturing process and as an analytical testing SME.